S&P 500   3,821.55
DOW   30,946.99
QQQ   283.54
S&P 500   3,821.55
DOW   30,946.99
QQQ   283.54
S&P 500   3,821.55
DOW   30,946.99
QQQ   283.54
S&P 500   3,821.55
DOW   30,946.99
QQQ   283.54

Celldex Therapeutics Stock Forecast, Price & News

-0.45 (-1.54%)
(As of 06/28/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
827,236 shs
Average Volume
627,152 shs
Market Capitalization
$1.34 billion
P/E Ratio
Dividend Yield
Price Target
30 days | 90 days | 365 days | Advanced Chart

Receive CLDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Celldex Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CLDX Stock Forecast (MarketRank)

Overall MarketRank

2.03 out of 5 stars

Medical Sector

564th out of 1,433 stocks

Diagnostic Substances Industry

7th out of 27 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
Celldex Therapeutics logo

About Celldex Therapeutics (NASDAQ:CLDX)

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.

CLDX Stock News Headlines

Celldex Therapeutics (NASDAQ:CLDX) Shares Gap Up to $23.65
Celldex Therapeutics (NASDAQ:CLDX) Shares Up 3.8%
See More Headlines

Industry, Sector and Symbol

Diagnostic substances
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
5 Analysts


Net Income
$-70.51 million
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$4.65 million
Book Value
$8.99 per share


Free Float
Market Cap
$1.34 billion

Social Links

Celldex Therapeutics Frequently Asked Questions

Should I buy or sell Celldex Therapeutics stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celldex Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Celldex Therapeutics stock.
View analyst ratings for Celldex Therapeutics
or view top-rated stocks.

What is Celldex Therapeutics' stock price forecast for 2022?

5 analysts have issued 12-month price objectives for Celldex Therapeutics' stock. Their CLDX stock forecasts range from $60.00 to $68.00. On average, they predict Celldex Therapeutics' stock price to reach $65.00 in the next twelve months. This suggests a possible upside of 126.6% from the stock's current price.
View analysts' price targets for Celldex Therapeutics
or view top-rated stocks among Wall Street analysts.

How has Celldex Therapeutics' stock price performed in 2022?

Celldex Therapeutics' stock was trading at $38.64 at the beginning of 2022. Since then, CLDX shares have decreased by 25.8% and is now trading at $28.69.
View the best growth stocks for 2022 here

When is Celldex Therapeutics' next earnings date?

Celldex Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Celldex Therapeutics

How were Celldex Therapeutics' earnings last quarter?

Celldex Therapeutics, Inc. (NASDAQ:CLDX) posted its quarterly earnings data on Thursday, May, 5th. The biopharmaceutical company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.46) by $0.03. The biopharmaceutical company had revenue of $0.17 million for the quarter, compared to the consensus estimate of $0.75 million. Celldex Therapeutics had a negative net margin of 1,860.46% and a negative trailing twelve-month return on equity of 20.68%.
View Celldex Therapeutics' earnings history

When did Celldex Therapeutics' stock split? How did Celldex Therapeutics' stock split work?

Celldex Therapeutics shares reverse split before market open on Monday, February 11th 2019. The 1-15 reverse split was announced on Friday, February 8th 2019. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 8th 2019. An investor that had 100 shares of Celldex Therapeutics stock prior to the reverse split would have 7 shares after the split.

Who are Celldex Therapeutics' key executives?

Celldex Therapeutics' management team includes the following people:
  • Mr. Anthony S. Marucci M.B.A., Founder, Pres, CEO & Director (Age 60, Pay $1.18M)
  • Dr. Tibor Keler, Founder, Chief Scientific Officer & Exec. VP (Age 63, Pay $748.51k)
  • Mr. Sam Martin, Sr. VP, CFO, Sec. & Treasurer (Age 51, Pay $619.35k)
  • Mr. Freddy A. Jimenez Esq., Sr. VP & Gen. Counsel (Age 53, Pay $579.7k) (LinkedIn Profile)
  • Dr. Diane C. Young M.D., Sr. VP & Chief Medical Officer (Age 65, Pay $636k)
  • Ms. Sarah Cavanaugh, Sr. VP of Corp. Affairs & Admin. (Age 47) (LinkedIn Profile)
  • Patrick Till, Sr. Director of Investor Relations & Corp. Communications
  • Dr. Ronald A. Pepin, Chief Bus. Officer & Sr. VP (Age 66)
  • Ms. Elizabeth Crowley, Chief Product Devel. Officer & Sr. VP (Age 50) (LinkedIn Profile)
  • Dr. Richard M. Wright Ph.D., Chief Commercial Officer & Sr. VP (Age 58)

What other stocks do shareholders of Celldex Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Celldex Therapeutics investors own include OPKO Health (OPK), Gilead Sciences (GILD), ACADIA Pharmaceuticals (ACAD), Corbus Pharmaceuticals (CRBP), Precigen (PGEN), Micron Technology (MU), Dynavax Technologies (DVAX), Exelixis (EXEL), bluebird bio (BLUE) and SCYNEXIS (SCYX).

What is Celldex Therapeutics' stock symbol?

Celldex Therapeutics trades on the NASDAQ under the ticker symbol "CLDX."

Who are Celldex Therapeutics' major shareholders?

Celldex Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (7.55%), RTW Investments LP (6.60%), BlackRock Inc. (6.52%), State Street Corp (5.74%), Vanguard Group Inc. (5.21%) and RA Capital Management L.P. (4.44%). Company insiders that own Celldex Therapeutics stock include Anthony S Marucci, Diane C Young, Elizabeth Crowley, Freddy A Jimenez, James J Marino, Margo Heath-Chiozzi, Richard M Wright, Samuel Bates Martin, Sarah Cavanaugh and Tibor Keler.
View institutional ownership trends for Celldex Therapeutics

Which institutional investors are selling Celldex Therapeutics stock?

CLDX stock was sold by a variety of institutional investors in the last quarter, including RTW Investments LP, Invesco Ltd., Candriam Luxembourg S.C.A., BlackRock Inc., Ghost Tree Capital LLC, First Trust Advisors LP, Northern Trust Corp, and Kiwi Wealth Investments Limited Partnership. Company insiders that have sold Celldex Therapeutics company stock in the last two years include Diane C Young, Elizabeth Crowley, Richard M Wright, Samuel Bates Martin, and Sarah Cavanaugh.
View insider buying and selling activity for Celldex Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Celldex Therapeutics stock?

CLDX stock was acquired by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Viking Global Investors LP, Kynam Capital Management LP, Woodline Partners LP, State Street Corp, RA Capital Management L.P., Polar Capital Holdings Plc, and Sessa Capital IM L.P..
View insider buying and selling activity for Celldex Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Celldex Therapeutics?

Shares of CLDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Celldex Therapeutics' stock price today?

One share of CLDX stock can currently be purchased for approximately $28.69.

How much money does Celldex Therapeutics make?

Celldex Therapeutics (NASDAQ:CLDX) has a market capitalization of $1.34 billion and generates $4.65 million in revenue each year. The biopharmaceutical company earns $-70.51 million in net income (profit) each year or ($1.710010) on an earnings per share basis.

How many employees does Celldex Therapeutics have?

Celldex Therapeutics employs 132 workers across the globe.

When was Celldex Therapeutics founded?

Celldex Therapeutics was founded in 1983.

How can I contact Celldex Therapeutics?

Celldex Therapeutics' mailing address is 53 FRONTAGE ROAD SUITE 220, HAMPTON NJ, 08827. The official website for Celldex Therapeutics is www.celldex.com. The biopharmaceutical company can be reached via phone at (908) 200-7500, via email at [email protected], or via fax at 908-454-1911.

This page (NASDAQ:CLDX) was last updated on 6/29/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.